Kobayashi Pharmaceutical Co., Ltd.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. carries a market capitalization of 405.15B, placing it among publicly traded companies globally. Its enterprise value stands at 348.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kobayashi Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. has 74.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. maintains a current ratio of 3.28, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Kobayashi Pharmaceutical Co., Ltd.'s stock has gained approximately 34.35% over the past 52 weeks. The 50-day moving average sits at 6,232.88, while the 200-day moving average is 5,784.65.

As of June 30, 2026, Kobayashi Pharmaceutical Co., Ltd. holds 57.33B in cash and equivalents against 723.00M in total debt, resulting in a net debt position of -47.03B. Total book value stands at 209.69B, with working capital of 86.76B providing operational flexibility.

Kobayashi Pharmaceutical Co., Ltd.'s most recent stock split took place on June 28, 2016 with a 1:2 split ratio.